Iterum Therapeutics
ITRM
ITRM was delisted on the 31st of March, 2026.
20 hedge funds and large institutions have $1.38M invested in Iterum Therapeutics in 2025 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 6 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
1.24% less ownership
Funds ownership: 4.48% → 3.23% (-1.2%)
17% less funds holding
Funds holding: 24 → 20 (-4)
37% less capital invested
Capital invested by funds: $2.18M → $1.38M (-$800K)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OIA
OneDigital Investment Advisors
Overland Park,
Kansas
|
+$150K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$15.9K |
| 3 |
CFD
Creative Financial Designs
Kokomo,
Indiana
|
+$14.9K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$8.34K |
| 5 |
SS
SBI Securities
Tokyo,
Japan
|
+$6 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$294K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$37.5K |
| 3 |
Jane Street
New York
|
-$18.2K |
| 4 |
Morgan Stanley
New York
|
-$7.8K |
| 5 |
AGM
Alpine Global Management
New York
|
-$7.42K |
ITRM Hedge Fund Activity: Q1 2025 in Review
20 institutional investors reported a position in Iterum Therapeutics (ITRM) for Q1 2025, worth a combined $1.38M — down 37% from $2.18M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ITRM and 2 opened new positions — a net loss of 4 holders — while 3 trimmed existing stakes and 3 added.
The largest buyer was OneDigital Investment Advisors, opening a new position worth an estimated $150K. The largest seller was Renaissance Technologies, cutting an estimated $294K.
- 20 institutional investors held Iterum Therapeutics (ITRM) as of Q1 2025, down from 24 in Q4 2024.
- Funds reported $1.38M of Iterum Therapeutics stock for Q1 2025, down 37% quarter-over-quarter.
- 2 funds opened new Iterum Therapeutics positions in Q1 2025 and 6 closed out, a net change of -4 holders.
- The largest Iterum Therapeutics buyer in Q1 2025 was OneDigital Investment Advisors, an estimated $150K added.
- The largest Iterum Therapeutics seller in Q1 2025 was Renaissance Technologies, an estimated $294K sold.
Based on aggregated 13F filings for Q1 2025.